Jennifer Ruhl

Jennifer Ruhl

Auto-generated profile, based on publicly available information

Jennifer Ruhl

Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
GFGonçalo Forjaz
Gonçalo Forjaz
LRLynn Ries
Lynn Ries
TDTheresa P. Devasia
Theresa P. Devasia
GFGretchen Flynn
Gretchen Flynn
JRJennifer Ruhl
Jennifer Ruhl
AMAngela B. Mariotto
Angela B. Mariotto
Background: Stage is the most important prognostic factor for understanding cancer survival trends. Summary stage (SS) classifies cancer based on the extent of spread: In situ, Localized, Regional, or Distant. Continual updating of staging systems poses challenges to stage comparisons over time. We use a consistent summary stage classification and present survival trends for 25 cancer sites using the joinpoint survival (JPSurv) model. Methods: We developed a modified summary stage variable, Long-Term Site-Specific Summary Stage, based on as consistent a definition as possible and applied it to a maximum number of diagnosis years, 1975–2019. We estimated trends by stage by applying JPSurv to relative survival data for 25 cancer sites in SEER-8, 1975–2018, followed through December 31, 2019. To help interpret survival trends, we report incidence and mortality trends using the joinpoint model. Results: Five-year relative survival improved for nearly all sites and stages. Large improvements were observed for localized pancreatic cancer [4.25 percentage points annually, 2007–2012 (95% confidence interval, 3.40–5.10)], distant skin melanoma [2.15 percentage points annually, 2008–2018 (1.73–2.57)], and localized esophagus cancer [1.18 percentage points annually, 1975–2018 (1.11–1.26)]. Conclusions: This is the first analysis of survival trends by summary stage for multiple cancer sites. The largest survival increases were seen for cancers with a traditionally poor prognosis and no organized screening, which likely reflects clinical management advances. Impact: Our study will be particularly useful for understanding the population-level impact of new treatments and identifying emerging trends in health disparities research.

11 July 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PKPraveen Kumar
Praveen Kumar
JRJennifer Ruhl
Jennifer Ruhl
TCTanvi V. Chiddarwar
Tanvi V. Chiddarwar
DGDavid U. Garibay-Treviño
David U. Garibay-Treviño
KCKrishna Roy Chowdhury
Krishna Roy Chowdhury
HJHawre Jalal
Hawre Jalal
Background: Coding changes in disease definitions have influenced trends in bladder cancer epidemiologic outcomes in registries. The Surveillance, Epidemiology, and End Results (SEER) Program introduced a harmonized staging variable (available from the SEER Program upon request) for long-term trend analysis. This study analyzes trends in bladder cancer incidence using the harmonized staging variable. Methods: Using SEER 12 registry data, we compared trends in the incidence of bladder cancer cases diagnosed from 1992 to 2019 using the revised (or harmonized) staging variable against the original staging variables (SEER modified AJCC third edition for 1992–2003, Derived AJCC sixth edition for 2004–2015, Derived SEER Combined for 2016–2017, and Derived EOD 2018 for 2018–2019). We used joinpoint regression to analyze changes in trends. Results: The data availability has improved with the revised staging system as the proportion of cases with missing lymph node and metastasis stages was substantially reduced. However, the trends varied by tumor stages between the two systems. There were generally more discontinuities in trends with the original system than with the revised system. Unlike the trend observed with the original staging system, the harmonized staging system has shown a 4% annual decrease in Tis incidence since 1992. Conclusions: With the revised variable, we observed a consistent decrease in the incidence of Tis cases, and the trends seem smoother. Impact: Our study highlights the benefits of using revised staging variables to reveal previously hidden patterns, supporting the use of new variables for a more nuanced understanding of temporal trends in epidemiology.

2 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MPMackenzie Price
Mackenzie Price
CKCarol Kruchko
Carol Kruchko
DBDaniel Brat
Daniel Brat
PCPatrick J. Cimino
Patrick J. Cimino
JHJason Thomas Huse
Jason Thomas Huse
QOQuinn T. Ostrom
Quinn T. Ostrom
Background: The Central Brain Tumor Registry of the United States (CBTRUS) uses a histology grouping model based on the World Health Organization (WHO) to classify cancer registry records for clinically relevant statistical reporting. Methods: CBTRUS, together with its consulting neuropathologists, reviewed and aligned its histology groupings with the 2021 WHO Classification update. Obsolete histology nomenclature along with their International Classification of Diseases for Oncology 3 rd edition (ICD-O-3) codes were identified, currently included histologies were reclassified as appropriate, and new codes found in 2021 WHO were incorporated. An evaluation was conducted of the frequency of histology codes affected in the reclassification process, as well as incidence and survival pre- and post-reclassification of CBTRUS Tumor Type Groupings. Results: After review of the CBTRUS grouping scheme, 205 codes were reclassified and 2 new codes were incorporated. Tumor type groups most affected were those classified as glioma. Reclassification resulted in 167,038 of 491,804 (34%) cases having a grouping reclassification or reporting change, indicating that the 2021 revision of the WHO Classification has significantly impacted the collection and reporting of primary b CNS tumors. Conclusion: This work demonstrates the need to be responsive to changes in classification and coding for statistics to reflect real-world clinical use. This will require collaboration from all parties to have the ability to reconcile clinical practices and surveillance requirements. KEY POINTS: Classification changes in cancer registration pose challenges to reporting clinically-relevant population-based epidemiologic statistics for central nervous system (CNS) tumors. The Central Brain Tumor Registry of the United States provides an example of aligning ICD-O-3 and 2021 WHO CNS classification with cancer registry reporting. Implementation of ICD-O-4 and the latest WHO (CNS6) will undoubtedly be challenging to cancer registry reporting yet will ultimately improve our understanding of these tumors and their impact on a population. IMPORTANCE OF THE STUDY: We performed this study to report on the Central Brain Tumor Registry of the United States (CBTRUS) tumor classification scheme which was revised to make it consistent with the 2021 WHO classification (CNS5) revision and to provide a roadmap for implementation of the recently published ICD-O 4 th edition. While we have previously published descriptive epidemiology for selected entities based on the CNS5 classifications, this is the first CBTRUS grouping scheme to include molecular information coded in the Brain Molecular Marker Site-Specific Data Item. LAY SUMMARY: Central nervous system (CNS) tumor classification systems help doctors, researchers, and cancer registries identify and track specific types of CNS tumors. When the World Health Organization (WHO) updated its CNS tumor classification in 2021, the Central Brain Tumor Registry of the United States (CBTRUS) reviewed and updated its reporting system to match these changes. More than 200 tumor codes were reclassified, affecting nearly one-third of CNS tumor records, and most heavily impacted gliomas. These updates improve the accuracy and clinical relevance of national CNS tumor statistics. Ongoing collaboration among treating physicians, pathologists, cancer registries, and researchers will be essential as future classification updates are implemented.

2 September 2025
Verified
Other
Open access
PKPraveen Kumar
Praveen Kumar
JRJennifer Ruhl
Jennifer Ruhl
TCTanvi V. Chiddarwar
Tanvi V. Chiddarwar
DGDavid U. Garibay-Treviño
David U. Garibay-Treviño
KCKrishna Roy Chowdhury
Krishna Roy Chowdhury
HJHawre Jalal
Hawre Jalal
Supplementary Figure S1 shows the comparison of age-adjusted incidence rates by N stage between the original and revised staging variables, using JoinPoint Regression Analysis.

2 September 2025
Verified
Other
Open access
PKPraveen Kumar
Praveen Kumar
JRJennifer Ruhl
Jennifer Ruhl
TCTanvi V. Chiddarwar
Tanvi V. Chiddarwar
DGDavid U. Garibay-Treviño
David U. Garibay-Treviño
KCKrishna Roy Chowdhury
Krishna Roy Chowdhury
HJHawre Jalal
Hawre Jalal
Supplementary Figure S2 shows the comparison of age-adjusted incidence rates by M stage between the original and revised staging variables, using JoinPoint Regression Analysis.

2 September 2025
Verified
Other
Open access
PKPraveen Kumar
Praveen Kumar
JRJennifer Ruhl
Jennifer Ruhl
TCTanvi V. Chiddarwar
Tanvi V. Chiddarwar
DGDavid U. Garibay-Treviño
David U. Garibay-Treviño
KCKrishna Roy Chowdhury
Krishna Roy Chowdhury
HJHawre Jalal
Hawre Jalal
Background:Coding changes in disease definitions have influenced trends in bladder cancer epidemiologic outcomes in registries. The Surveillance, Epidemiology, and End Results (SEER) Program introduced a harmonized staging variable (available from the SEER Program upon request) for long-term trend analysis. This study analyzes trends in bladder cancer incidence using the harmonized staging variable.Methods:Using SEER 12 registry data, we compared trends in the incidence of bladder cancer cases diagnosed from 1992 to 2019 using the revised (or harmonized) staging variable against the original staging variables (SEER modified AJCC third edition for 1992–2003, Derived AJCC sixth edition for 2004–2015, Derived SEER Combined for 2016–2017, and Derived EOD 2018 for 2018–2019). We used joinpoint regression to analyze changes in trends.Results:The data availability has improved with the revised staging system as the proportion of cases with missing lymph node and metastasis stages was substantially reduced. However, the trends varied by tumor stages between the two systems. There were generally more discontinuities in trends with the original system than with the revised system. Unlike the trend observed with the original staging system, the harmonized staging system has shown a 4% annual decrease in Tis incidence since 1992.Conclusions:With the revised variable, we observed a consistent decrease in the incidence of Tis cases, and the trends seem smoother.Impact:Our study highlights the benefits of using revised staging variables to reveal previously hidden patterns, supporting the use of new variables for a more nuanced understanding of temporal trends in epidemiology.